Amylin and amylin agonists for treating schizophrenia
Disclosed is the use of an amylin peptide or an amylin agonist peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1-31, 33, 35-67, 80-83, and 86-253 for the preparation of a medicament for the treatment of schizophrenia. (62) Divided Out of 561936
Saved in:
| Main Authors | , , , , |
|---|---|
| Format | Patent |
| Language | English |
| Published |
26.03.2010
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Disclosed is the use of an amylin peptide or an amylin agonist peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1-31, 33, 35-67, 80-83, and 86-253 for the preparation of a medicament for the treatment of schizophrenia. (62) Divided Out of 561936 |
|---|---|
| AbstractList | Disclosed is the use of an amylin peptide or an amylin agonist peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1-31, 33, 35-67, 80-83, and 86-253 for the preparation of a medicament for the treatment of schizophrenia. (62) Divided Out of 561936 |
| Author | LAUGERO, KEVIN D MACK, CHRISTINE M PARKES, DAVID G HANLEY, MICHAEL YOUNG, ANDREW A |
| Author_xml | – fullname: YOUNG, ANDREW A – fullname: HANLEY, MICHAEL – fullname: MACK, CHRISTINE M – fullname: LAUGERO, KEVIN D – fullname: PARKES, DAVID G |
| BookMark | eNrjYmDJy89L5WQwdcytzMnMU0jMS1FIhDLT8_Myi0uKFdLyixRKilITSzLz0hWKkzMyq_ILMopS8zITeRhY0xJzilN5oTQ3g5yba4izh25qQX58anFBYnJqXmpJvF-UqbmFkaWlozFBBQB98S5d |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| ExternalDocumentID | NZ578299A |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_NZ578299A3 |
| IEDL.DBID | EVB |
| IngestDate | Fri Jul 19 13:59:20 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_NZ578299A3 |
| Notes | Application Number: NZ20060578299 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100326&DB=EPODOC&CC=NZ&NR=578299A |
| ParticipantIDs | epo_espacenet_NZ578299A |
| PublicationCentury | 2000 |
| PublicationDate | 20100326 |
| PublicationDateYYYYMMDD | 2010-03-26 |
| PublicationDate_xml | – month: 03 year: 2010 text: 20100326 day: 26 |
| PublicationDecade | 2010 |
| PublicationYear | 2010 |
| RelatedCompanies | AMYLIN PHARMACEUTICALS, INC |
| RelatedCompanies_xml | – name: AMYLIN PHARMACEUTICALS, INC |
| Score | 2.7607727 |
| Snippet | Disclosed is the use of an amylin peptide or an amylin agonist peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1-31, 33, 35-67, 80-83, and... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | Amylin and amylin agonists for treating schizophrenia |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100326&DB=EPODOC&locale=&CC=NZ&NR=578299A |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LT8MwDLbGQMANxvsx9YB6i0jTrmoPFdr60IREN6GBpl2mpCTTDmwTLUL8e5zQwS67WYnkPBTHdmx_AbhzFOWhqwriMiWJxzglvAgUkYrSgiqPKm6yfHO__-I9jjvjBszWtTAGJ_TLgCOiRBUo75W5r1f_j1iJya0s78Ucm5YP2ShK7No7dvCMMt9OelE6HCSD2I7jKJ_Y-XOkUdvDsLsDu9qG1iD76WtPl6SsNvVJdgR7Q2S1qI6hIRctOIjX3661YP-pjnYjWQteeQKd7vs3GoQW-v0Wr8nZUqPelhaanZbJF0ctZJWbSXSn0M7SUdwnOP70b6XTfFLP0z2DJrr_8gIsRygZ6HBr6HBPFIEQb1SiUmXKZ6EvOpdwvoXJ1daeazj8jYK7hPk30Kw-PuUtKtdKtM3G_ABHU4EP |
| link.rule.ids | 230,309,786,891,25594,76906 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LT8MwDLbGQIwbjPdj9IB6q0jTB-2hQlu7qsDWTaigaZep6ZKJA9tEixD_Hjd0sMtuViI5D8WxHdtfAG50QVLXEJlmUME1k6ZESzNHaFwQkhFhEpHKLN_Yjl7Mx5E1qsFsVQsjcUK_JDgiSlSG8l7I-3r5_4gVyNzK_Ja9YdPiPky8QK28Yx3PKLXVoON1h4Ng4Ku-78VjNX72StR2121vwfZdCc1b2k2vnbIkZbmuT8J92Bkiq3lxADU-b0LDX3271oTdfhXtRrISvPwQrPb7NxqECvr9SlqRs0WJepsraHYqMl8ctZCSryfRHUEr7CZ-pOH4k7-VTuJxNU_jGOro_vNTUHQmuFOGW109NVnmMDYlHJUqFTZ1bWadwckGJucbe66hESX93qT3ED9dwN5vRNzQqH0J9eLjk1-hoi1YS27SD3jZg_w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Amylin+and+amylin+agonists+for+treating+schizophrenia&rft.inventor=YOUNG%2C+ANDREW+A&rft.inventor=HANLEY%2C+MICHAEL&rft.inventor=MACK%2C+CHRISTINE+M&rft.inventor=LAUGERO%2C+KEVIN+D&rft.inventor=PARKES%2C+DAVID+G&rft.date=2010-03-26&rft.externalDBID=A&rft.externalDocID=NZ578299A |